CardieX (ASX: CDX) CEO Craig Cooper joined Steve Darling from Proactive Vancouver to discuss a number of updates with the company including the use of their XCEL SphygmoCor device by researchers in a clinical study by the Artery Society on COVID and arterial stiffness.
Cooper discusses that study and also gave Proactive some new information regarding Swiss company Roche selecting CardieX co-development partner Blumio for a medical-grade diagnostic sensor pilot program and Blumio's new development agreement with Infineon.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CardieX Ltd named herein, including the promotion by the Company of CardieX Ltd in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE